ClinicalTrials.gg
WithdrawnNCT06015750RESTOREUpdated Dec 18, 2025

Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

A Phase 4 interventional study of methotrexate and rituximab in Hypophosphatasia, sponsored by Alexion Pharmaceuticals, Inc.. Withdrawn. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Sponsor decision following FDA release from the PMR.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Hypophosphatasia by AstraZeneca — 4 open to participants now, 7 under way, 3 of them phase 3. Hypophosphatasia · AstraZeneca.

Enrollment
14th of 16
0 · median 13
Started
2026
with 1 other
Phase 4
3 of 25
none open now
Registered
20th of 25
by date

Among the 25 studies in Hypophosphatasia by AstraZeneca, this one is the 14th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 in phase 4, and was the 20th registered.

Hypophosphatasia

46 studies on the registry are indexed under Hypophosphatasia; 11 are open to participants now.

Browse Hypophosphatasia studies →

Open to participants now

4 of the 25 studies in Hypophosphatasia by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 9 Hypophosphatasia studies recruiting now, 8 set no upper age limit and 1 stops at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Hypophosphatasia by AstraZeneca, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effect of immunosuppressive therapy (IST) in participants treated with asfotase alfa who demonstrate immune-mediated loss of effectiveness (LoE).

Read the detailed description

The administration of biological drugs to patients, especially for chronic conditions, carries a risk of eliciting anti-drug antibodies. Neutralizing antibodies can neutralize the clinical benefit of the agent. In postmarketing safety surveillance, some patients treated with asfotase alfa demonstrated an initial response, but subsequently recurrence and progression of disease. Consequently, the FDA requested a study to assess a potential serious risk of immune-mediated loss of effectiveness.

03

Conditions studied

  • Hypophosphatasia

Browse trials for

Keywords

  • Hypophosphatasia
  • HPP
  • Asfotase alfa
  • Strensiq
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Reoccurrence or worsening of rickets for at least the past 3 months in participants who showed an initial efficacy response to asfotase alfa after at least 6 months of continuous treatment and currently receiving asfotase alfa. RSS will be used to determine severity at Baseline.
  • Presence of ADAs, with or without NAbs, irrespective of their titers.
  • Confirmation by the TMB that both the clinical evidence and immunogenicity-mediated association noted above are present.
  • Female participants of and male participants with partners of childbearing potential must follow protocol-specified guidance as described in Section 10.5.
  • Participant, or participant's legal guardian, is capable of signing or assent as described in Section 10.1.3, which includes compliance with the requirements and restrictions listed in the informed consent or assent form and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Known history of (HIV) infection (evidenced by HIV type 1 or type 2 [HIV 1, HIV 2] antibody) or or C viral infection.
  • Known or suspected history of drug or alcohol abuse or dependence within 1 year prior to Screening.
  • Inability of the participant, or the participant's legal guardian, to provide .
  • Pregnant, breastfeeding, or intending to conceive during the course of the study.
  • Inability to travel to the clinic for specified visits during the Treatment Period caused by disease per se or logistics (does not apply to external travel restrictions).
  • The participant is at risk of reactivation or has an active significant viral infection such as hepatitis B, cytomegalovirus, herpes simplex, human polyomavirus (also known as John Cunningham [JC] virus), parvovirus, or Epstein Barr virus.
  • The participant is at risk of reactivation of tuberculosis or has regular contact (eg, in the household) with individuals who are being actively treated for tuberculosis.
  • The participant has had or is required to have any within 1 month prior to enrollment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Pediatric participants with HPP

    Pediatric participants who have been receiving asfotase alfa treatment for their HPP, and who demonstrate immune-mediated LoE.

    Drug: methotrexate · Drug: rituximab · Drug: bortezomib · Drug: IVIg · Drug: Folic Acid

Interventions

  • Methotrexate will be administered SC or orally weekly for 104 weeks.

  • Rituximab will be administered intravenously (IV) continuously weekly, for up to 74 weeks.

  • Bortezomib will be administered via IV bolus or SC, as needed.

  • DrugIVIg

    IVIg will be administered via IV monthly through initial 74 weeks.

  • Folic acid will be given orally as long as methotrexate is being dosed.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieve Immunosuppressive Therapy (IST) Complete Response at Week 100

    Time frame: Week 100

Secondary outcomes

  1. Number Participants with Antidrug Antibodies (ADAs) and Neutralizing Antibodies (NAbs)

    Time frame: Baseline Through Week 100

  2. ADA and NAb Titer Levels

    Time frame: Baseline Through Week 100

  3. Serum Concentration of Asofatase Alfa (Measured as Enzyme Activity)

    Time frame: Baseline Through Week 100

  4. Plasma Concentration of Pyridoxal-5ˈ-Phosphate (PLP)

    Time frame: Baseline Through Week 100

  5. Plasma Concentration of Inorganic Pyrophosphates (PPi)

    Time frame: Baseline Through Week 100

  6. Number of Participants with Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events

    Time frame: Baseline Through Week 104

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Mar 2030, 43 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2023
First posted
Aug 29, 2023
StartEst.
Jul 29, 2026
Primary completionEst.
Mar 13, 2030
CompletionEst.
Mar 13, 2030
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06015750
Responsible party
Sponsor
First posted
Aug 29, 2023
Start date
Jul 29, 2026 (estimated)
Primary completion
Mar 13, 2030 (estimated)
Completion
Mar 13, 2030 (estimated)
Last update
Dec 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methotrexate · Rituximab · Bortezomib · Immunoglobulins, Intravenous · Folic Acid

Start the discussion